Reframing DCIS: from diagnosis to prevention opportunity
The ASCO Post examines the scientific rationale behind treating DCIS as a prevention opportunity rather than a cancer requiring immediate surgery — covering the RECAST trial and the growing movement toward active surveillance as a standard option.
The RECAST DCIS trial is helping reshape the conversation around Ductal Carcinoma in Situ (DCIS) by exploring whether some patients can safely avoid immediate surgery. Instead of viewing every DCIS diagnosis as cancer requiring aggressive treatment, researchers are investigating whether selected low-risk cases can be managed through active surveillance and preventive strategies. Featured in The ASCO Post, the article highlights the scientific foundation of the RECAST trial and its potential to transform breast cancer prevention. By focusing on risk assessment, personalized care, and careful monitoring, the study aims to reduce unnecessary treatment while maintaining excellent patient outcomes. The RECAST approach reflects a broader shift toward precision medicine—empowering patients and clinicians to make informed decisions based on the biology of the disease rather than relying solely on traditional treatment pathways. If successful, this research could establish active surveillance as a safe and effective option for appropriately selected patients with DCIS.